Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673457 | 0.89 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL1641308 | 0.89 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL1641052 | 0.89 | HRH3 (1.00) | HRH3KCNH2 | |
| Bromide SCHEMBL5838754 | 0.88 | HRH3 (0.98) | HRH3KCNH2 | |
| Fumaric Acid SCHEMBL5838446 | 0.88 | HRH3 (0.86) | HRH3KCNH2 | |
| Sulfuric Acid SCHEMBL5838882 | 0.86 | HRH3 (0.91) | HRH3KCNH2 | |
| SCHEMBL1641267 | 0.86 | HRH3 (0.94) | HRH3KCNH2 | |
| SCHEMBL1641271 | 0.86 | HRH3 (0.94) | HRH3KCNH2 | |
| Salicylic Acid SCHEMBL5839146 | 0.84 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL5838195 | 0.81 | HRH3 (0.80) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7145005-B2 | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBOTT LABORATORIES (US) | 2006-12-05 | — | — | US | claimed |
| US-20050256127-A1 | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBVIE INC. | 2005-11-17 | — | — | US | claimed |
| US-7145005-B2 | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBOTT LABORATORIES (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050256127-A1 | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBVIE INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256127-A1 | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2J2, NUP188 | HRH3 3738/4885KCNH2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.